Medtronic prices a mature device maker, but Q1 growth and cash set the test

Summary: U.S. long Watchlist. Medtronic plc (NYSE: MDT) was quoted at $90.65 in an after-hours finance-feed context at 2026-08-31 23:15:00 UTC, down 0.61% from the provider's prior close. The market has a sound reason to be cautious: fiscal 2026 non-GAAP operating margin fell, tariffs and a MiniMed payment absorbed margin, and the Diabetes separation structure is not final. The less obvious counterpoint is that fiscal fourth-quarter organic revenue grew 6.6%, Cardiac Ablation Solutions grew 78% globally and 124% in the U.S., fiscal 2027 guidance calls for 6.75% to 7.25% organic revenue growth and $5.90 to $6.00 of non-GAAP EPS, and fiscal 2026 free cash flow was $5.426 billion. The next test is the Q1 FY27 release at about 5:45 a.m. CT on September 1, 2026. A clean print and a stable cash and separation bridge could support a re-rating. The pre-print entry and five-percent adverse bound remain unverified. This is research, not personalized financial advice.

Run timestamp: 2026-09-01T07:31:34+08:00 (Asia/Singapore). Quote time, filing dates, catalyst dates, and document-write time are separate.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Medtronic (MDT)	Long	The tape prices mature medtech, separation uncertainty, and margin drag while Q4 growth, FY27 guide, product share gains, and recurring cash point to a cleaner operating state	June 3 FY26 primary release and current Sept. 1 Q1 FY27 schedule	Q1 FY27 results and call on Sept. 1, then segment, margin, cash, and Diabetes-separation follow-through	Large liquid NYSE name with a dividend record, but current short, options, dealer, fund-flow, and order-book evidence are missing	Watchlist: reference-only base +13.62%, modeled bottom -4.58%, execution incomplete	12,622,510 shares in the finance-feed context; after-hours price and live execution fields are unverified	Q1 miss, guide cut, persistent margin pressure, or a costly Diabetes separation overwhelms the growth case
2	Palo Alto Networks (PANW)	Long	Strong Q3 revenue, NGS ARR, RPO, and cash flow precede the Sept. 1 print, but the provider multiple is extreme and acquired economics are still being absorbed	June 2 Q3 release and Aug. 3 event notice	FY26 results after the U.S. close on Sept. 1	8,798,842 shares in the finance-feed context; direct positioning and option-chain data are missing	Reject for this screen: a +10% base is plausible, but credible valuation downside exceeds 5%	Highly liquid, but the event gap can dominate	Growth can beat while multiple compression and acquisition charges overwhelm the print
3	Daktronics (DAKT)	Long	Record orders and backlog support a project-conversion story ahead of Sept. 2 results, but the valuation and small-cap project timing leave a wide adverse path	Aug. 26 event notice and June 24 FY26 results	Q1 FY27 results before the market opens on Sept. 2	404,959 shares in the finance-feed context; spread, depth, and exit liquidity are unverified	Reject for this screen: reference-only base +15.20%, modeled bottom -7.84%, and project concentration fail the adverse test	Smaller Nasdaq name with thinner execution evidence	Backlog timing, margin mix, or working capital disappoints
4	BlackBerry (BB)	Long	Q1 revenue, EBITDA, and operating cash improved sharply, but Secure Communications ARR was flat and the next Q2 catalyst is only planned for Sept. 24	June 25 Q1 FY27 release and current investor calendar	Q2 FY27 planned earnings around Sept. 24	7,939,816 shares in the finance-feed context; direct positioning and liquidity evidence are missing	Reject for this screen: base can exceed 10%, but valuation, flat ARR, and an unconfirmed date leave adverse risk above 5%	Liquid enough for a screen, but event-sensitive	Q2 QNX or Secure Communications growth fails to convert into durable cash

Selected opportunity: Medtronic plc (MDT), NYSE ordinary shares.

Why this one now: The catalyst is the closest of the credible long candidates, and the primary evidence provides an unusually complete bridge between organic growth, product share, cash flow, dividend policy, one-time costs, and the unresolved Diabetes separation. MDT is not selected because a dividend is a valuation argument. It is selected because a Q1 print can quickly tell the market whether the FY27 guide is a real operating reset or merely a favorable comparison with substantial exclusions.

What should surprise the reader: The positive surprise would be that a diversified medtech platform is compounding above its mature-company label while the largest growth businesses carry the quarter. The negative surprise would be that the strong Q4 and FY27 guide are mostly currency, calendar, M&A, and separation scaffolding, while underlying margin and cash conversion do not improve.

Why This Is the Best Opportunity Right Now

Medtronic's June 3 fiscal 2026 release supplied the setup before the September 1 Q1 FY27 print. Fiscal fourth-quarter revenue was $9.807 billion, up 6.6% organically, with cardiovascular revenue up 10.1% organically. Cardiac Ablation Solutions grew 78% globally, including 124% in the U.S., and gained eight points of U.S. share. This is operating evidence from a large installed-base business, not an uncontracted product promise. Medtronic FY26 fourth-quarter results

The same release guided fiscal 2027 organic revenue growth to 6.75% to 7.25% and diluted non-GAAP EPS to $5.90 to $6.00, or 6.7% to 8.5% growth. The guide includes a 53rd week, increased M&A, tariffs, interest, taxes, foreign exchange assumptions, and full-year Diabetes consolidation. At the midpoint, the $90.65 reference is about 15.2 times the non-GAAP EPS guide. That comparison is not like-for-like with the finance-feed trailing P/E of 25.32, because one is a forward management measure and the other is a provider's trailing measure. It is a valuation tension, not a completed fair-value calculation. Medtronic FY26 fourth-quarter results, Yahoo Finance MDT quote

Cash is the second leg. Fiscal 2026 operating cash flow was $7.330 billion, free cash flow was $5.426 billion, cash and investments were $9.2 billion, and the company returned $4.2 billion to shareholders. The 49th consecutive dividend increase raised the quarterly dividend to $0.72. These figures make a positive Q1 print more valuable if the cash bridge stays intact, but they do not remove product, regulatory, separation, or denominator risk. Medtronic FY26 fourth-quarter results, Medtronic FY26 financial schedules

Why This Can Move More Than 5% Soon

Medtronic's official investor page schedules the Q1 FY27 press release and presentation for approximately 5:45 a.m. CT on September 1, with a video earnings and Q&A broadcast at 6:45 a.m. CT. The release can test four linked variables in one morning: organic growth by portfolio, non-GAAP and GAAP margin, the full-year guide, and the cash and Diabetes-separation state. Medtronic Investor Relations overview

The price does not need a heroic new product to move ten percent. It needs the market to update its estimate of the durability of the guide. If Q1 confirms growth near the 6.75% to 7.25% framework, protects margins after the MiniMed payment and tariffs, and narrows the Diabetes separation path without a new cash burden, the current mature-company multiple can move toward the guide rather than the trailing history. If any one of those conditions fails, the same valuation comparison works in reverse.

10/5 Asymmetry Gate

The consistent measurement basis is a reference-only $90.65 after-hours quote, because entry.price is null until a fresh regular-session market audit and the Q1 state are verified. The holding window is the next 90 calendar days, subject to earlier invalidation.

Favorable base move: $103.00 / $90.65 - 1 = +13.62%.
Modeled adverse move: 1 - $86.50 / $90.65 = 4.58%.
Gross base-to-adverse ratio: 2.98:1 before spread, slippage, carry, taxes, and other costs.
Reference-only weighted price: 0.25 x $111.00 + 0.50 x $103.00 + 0.25 x $86.50 = $100.875, or +11.28% from the reference.
Net EV: Cannot be computed responsibly. There is no verified executable entry, live spread, depth, exit-liquidity estimate, Q1 result, current balance-sheet refresh, separation cash bridge, or current claim denominator.

The 4.58% modeled adverse case is not a promise that MDT cannot fall more than 5%. An earnings gap, product or regulatory setback, tariff shock, separation cost, or broad healthcare de-rating can exceed it. The five-percent adverse bound is therefore unproven, and the status is Watchlist.

What Should Surprise the Reader

The positive surprise is a clean conversion of the existing framework. Q1 organic revenue lands near the FY27 guide, the strongest Cardiovascular and Diabetes products keep carrying growth, margins are stable after known charges, and management gives a more concrete Diabetes separation path without sacrificing cash generation. The market then has evidence that MDT is not merely a yield vehicle.

The negative surprise is that Q4 was the high-water mark. Q1 organic growth slows, price and mix fail to offset tariffs, the reported margin relies on exclusions, and the Diabetes separation requires more stranded cost or capital than the current guide implies. The dividend can continue while the stock de-rates.

The Setup

Medtronic is a global medical-device company listed on the NYSE. Its fiscal 2026 portfolio showed a useful internal split. Cardiovascular revenue was $3.797 billion in Q4 and grew 10.1% organically. Neuroscience grew 3.0% organically, Medical Surgical grew 5.1%, and Diabetes grew 8.1% organically. Q4 organic growth was broad enough to matter, but not uniform enough to justify a single segment multiple. Medtronic FY26 financial schedules

The strongest product evidence was cardiac ablation. The Q4 release reported 78% global growth and 124% U.S. growth, with an additional eight points of U.S. share. Medtronic also highlighted Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS as growth opportunities. These are pipeline and product-adoption signals; they become common-share evidence only through revenue, margin, cash, and denominator follow-through. Medtronic FY26 fourth-quarter results

The separation risk is explicit. The company said the Diabetes business separation is expected through capital-markets transactions that may include a spin-off, split-off, offering, or combination, and that a final decision had not been reached as of the Q4 release. Q1 can change that uncertainty, but until it does, the current cash and investment pool cannot be allocated precisely between continuing MDT and the separated business.

The Market Price

At 2026-08-31 23:15:00 UTC, the finance-feed context showed:

Field	MDT context
Price	$90.65
Change	-$0.56, -0.61383%
Open	$90.67
Intraday high / low	$91.50 / $90.05
Intraday volume	12,622,510
Provider market capitalization	$116.893B
Provider P/E / EPS	25.3212 / $3.58
Session	After-hours context feed; intraday fields refer to the regular session
Execution state	Top-of-book, spread, depth, venue, volume quality, and exit liquidity unverified

Source: Yahoo Finance MDT quote, observed at the timestamp above. The finance feed is current context, not an executable order book.

The Mispricing

The market appears to price MDT through a mature-medtech lens: modest long-term growth, tariff and margin pressure, a complex Diabetes separation, and a trailing multiple that does not look cheap against the provider's reported EPS. That view is reasonable. Fiscal 2026 non-GAAP operating profit grew only 2.4%, non-GAAP operating margin fell 130 basis points, and constant-currency non-GAAP operating profit fell 0.6%. Medtronic FY26 fourth-quarter results

The disagreement is that the operating portfolio is changing faster than the label. Cardiovascular grew double digits organically, Cardiac Ablation took U.S. share, FY27 organic growth guidance is above the recent mature-company base, and cash conversion remains strong. The market may be using the trailing EPS history as if it were the FY27 operating state, while management is using a forward non-GAAP guide that includes explicit costs and calendar effects.

This can still be a false disagreement. The guide includes a 53rd week, increased M&A, full-year Diabetes consolidation, and tariff and interest effects. A forward non-GAAP multiple is not a cash claim. The market is right if the bridge requires too many adjustments to hold.

The Positioning

The current finance-feed volume was 12.6 million shares, but volume alone does not reveal who is buying or selling. Direct short interest, utilization, borrow cost, options open interest, dealer exposure, fund flows, and current holder concentration were not verified for this run. The positioning score is capped at 3/5.

There is one observable issuer behavior: a long dividend history and a large shareholder-return program. The Q4 release reports $4.2 billion returned to shareholders in FY26 and a higher quarterly dividend, but it does not establish that a current buyback will absorb event supply. A dividend record is context, not a forced flow. Medtronic FY26 fourth-quarter results

The positioning tension is an inference: event-driven healthcare funds may wait for the Q1 print and the Diabetes path before underwriting a higher multiple, while long-duration holders may value the cash and product breadth. No direct flow evidence supports that inference.

The Catalyst

The catalyst ladder is observable:

Q1 FY27 release: The official IR page schedules the press release and presentation for about 5:45 a.m. CT on September 1, 2026, followed by Q&A at about 6:45 a.m. CT. Test revenue, organic growth, portfolio mix, GAAP earnings, non-GAAP reconciliation, margin, and the FY27 guide. Medtronic Investor Relations overview
Growth quality: Test whether Cardiac Ablation, Cardiac Rhythm and Heart Failure, Acute Care and Monitoring, Diabetes, and other highlighted products continue to produce revenue and share gains rather than only pipeline language. Medtronic FY26 financial schedules
Margin and cash: Reconcile tariffs, the MiniMed Blackstone payment, M&A, litigation, restructuring, operating cash, capex, working capital, and any separation costs. Q4 non-GAAP margin fell despite revenue growth, so this is the first earnings-quality test.
Diabetes separation: Require a final or narrowed structure, timetable, stranded-cost assumptions, capital allocation, and cash ownership. A separation headline without a cash and denominator bridge is incomplete.
Per-share follow-through: Use the next filing to reconcile ordinary shares, employee awards, M&A consideration, repurchases, and the current denominator. A dividend increase is not denominator shrinkage.

The cheapest falsification is the Q1 release. If revenue, margin, cash, and the separation bridge do not support the FY27 guide, the re-rating case ends before a long expression is considered.

The Payoff

The base case is a confirmation trade in the analytical sense, not a command to buy. Q1 lands near the FY27 growth framework, the highest-growth product areas remain visible, non-GAAP margin does not deteriorate beyond the known charge structure, and management narrows the Diabetes separation path. The stock can re-rate from a trailing mature-company label toward a forward cash-generative medtech multiple.

The top case adds a guide raise, stronger Cardiac Ablation and Cardiovascular mix, cleaner cash conversion, and a separation structure that reduces uncertainty without a material stranded-cost burden. The bottom case is a soft print or unresolved separation that leaves the mature-company discount intact. An earnings gap or regulatory surprise can exceed the modeled bottom.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	25%	$111.00	+22.45% from $90.65	Next 90 days	Q1 confirms or raises organic growth, key products sustain share gains, margin and cash hold, and the Diabetes separation becomes more legible	Medium
Base Case	50%	$103.00	+13.62% from $90.65	Next 90 days	Q1 is near guide, margin is mixed but controlled, cash remains strong, and the market gives partial credit to the forward operating state	Medium
Bottom Case	25%	$86.50	-4.58% from $90.65	Next 90 days	Q1 is soft or separation uncertainty persists, but the diversified operating and cash base prevents a full thesis break	Low to Medium
Invalidation	n/a	Insufficient data	Thesis state failure, not a price stop	Before entry or during window	Q1 cuts the guide, recurring margin and cash weaken, separation costs rise materially, the denominator changes unfavorably, or market execution remains unverified	High

Probability-weighted expected value: Price-only weighted target = $100.875, or +11.28% from the $90.65 reference. Net EV cannot be computed because entry.price is null and the after-hours quote, live execution costs, Q1 result, current claims, separation cash bridge, and denominator are incomplete.

Current market level and timestamp: $90.65 at 2026-08-31 23:15:00 UTC, after-hours finance-feed context.

Primary instrument: MDT NYSE ordinary shares.

10/5 favorable base move: +13.62%, reference-only.

10/5 credible adverse move: -4.58% in the modeled bottom case, with an unmodeled event and regulatory tail beyond 5%.

10/5 measurement basis: Reference-only, not verified entry.

10/5 status: Watchlist, not Trade-qualified.

Confidence: Medium-low. The Q4 evidence and next-day catalyst are strong, but the print is pending, non-GAAP and calendar effects matter, the Diabetes separation is unresolved, direct positioning data are missing, and the reference-only adverse bound is not proven.

The Kill Shot

The strongest counterparty argument is that the market is not confused. It is correctly discounting a company whose Q4 non-GAAP operating margin fell 230 basis points year over year to 25.5%, with 160 basis points from a MiniMed Blackstone payment and 80 basis points from tariffs. Fiscal-year constant-currency non-GAAP operating profit also declined. The 6.75% to 7.25% FY27 organic guide includes a 53rd week, M&A, Diabetes consolidation, and other adjustments. A 15.2 times multiple on non-GAAP guide EPS can be an optical comparison rather than a durable valuation gap. Medtronic FY26 fourth-quarter results

The load-bearing assumption is that the growth portfolio is becoming large and durable enough to offset the separation and margin noise. If Q1 says otherwise, the cash and dividend can remain intact while the stock's multiple contracts.

The market may already know Cardiac Ablation is growing fast. The missing piece is not awareness of the product. It is whether the product mix, recurring cash, and separation design change the common-share economics.

What Could Go Wrong

Q1 revenue, organic growth, or non-GAAP EPS can miss the FY27 framework and trigger a gap before an orderly exit is available.
Cardiovascular growth can slow, or Cardiac Ablation share gains can require pricing, sales, or R&D investment that weakens margin.
Tariffs, foreign exchange, interest, taxes, litigation, restructuring, and M&A can keep adjusted growth from becoming GAAP or common cash.
The $9.2 billion cash and investment figure can be allocated partly to debt, acquisitions, separation costs, or business obligations rather than continuing-common shareholder returns.
The Diabetes separation can create stranded costs, duplicate infrastructure, or an unfavorable cash and denominator outcome; the structure was not final at the Q4 release.
A product, regulatory, reimbursement, manufacturing, or patient-safety event can damage a portfolio that otherwise looks diversified.
The FY27 guide can benefit from the 53rd week and full-year consolidation without proving an improved underlying run rate.
The market can de-rate healthcare or large-cap medtech even if MDT executes operationally.
The after-hours quote, spread, depth, venue quality, volume quality, and exit liquidity are not verified; a gap or halt can bypass a planned percentage control.

What Would Prove This Wrong

Remove the thesis or keep it blocked if:

The September 1 release cuts the FY27 organic-growth or EPS guide, or reveals Q1 growth below the portfolio evidence without a credible explanation.
Q1 margins deteriorate after separating known MiniMed, tariff, M&A, litigation, and restructuring items, and operating cash does not support the guide.
The Diabetes separation requires materially more cash, stranded cost, debt, or dilution than the current framework implies.
Cardiac Ablation and Cardiovascular share gains fail to translate into revenue, margin, and cash, or a regulatory or product issue changes the operating state.
The next filing shows an unfavorable ordinary-share denominator, M&A claim, repurchase, or cash allocation that offsets the operating improvement.
The market-structure audit cannot verify a regular-session quote, bid, ask, spread, depth, venue, volume quality, and realistic exit before any entry decision.

These are thesis invalidation and execution-cancellation tests. Price strength is not operating proof, and a price decline is not automatically thesis failure.

Risk Audit

Risk	What is known	Control
Earnings event	Q1 FY27 release is scheduled for Sept. 1 at about 5:45 a.m. CT; the result is not yet available	Wait for the release, call, and reconciliation before changing status
Growth quality	Q4 organic growth was 6.6%; Cardiac Ablation grew 78% globally and 124% in the U.S.; FY27 guide is 6.75% to 7.25%	Test segment growth, product mix, pricing, volume, and share gains in Q1
Margin	Q4 non-GAAP operating margin fell 230 bps, with MiniMed and tariff effects	Reconcile known charges to GAAP, non-GAAP, and cash; do not rely on adjusted EPS alone
Separation	Diabetes structure was not final; possible spin-off, split-off, offering, or combination remains open	Require structure, timetable, stranded costs, cash ownership, claims, and denominator
Cash and claims	FY26 FCF was $5.426B and cash and investments were $9.2B, but acquisitions and separation can consume cash	Use the next cash-flow and balance-sheet filing; do not treat cash as per-share value without claims and denominator
Positioning	Volume is observable; direct short, options, dealer, fund-flow, and holder evidence is missing	Cap positioning at 3/5; do not infer forced buying from volume
Market structure	$90.65 is an after-hours context quote; top-of-book, spread, depth, venue, and exit are unverified	Keep `entry.price` null and `execution.can_execute` false
Gap and event risk	Q1 can reprice the stock outside regular-session exit assumptions	Do not rely on a percentage stop to contain a gap, halt, or unavailable liquidity

The residual tail includes regulatory action, reimbursement changes, product safety, manufacturing, currency, tax, geopolitical, litigation, separation, and broad healthcare valuation risk. The $86.50 bottom is a scenario level, not a protection mechanism.

Best Trade Strategy

This is a Watchlist research expression, not an executable trade.

Instrument: MDT NYSE ordinary shares only.
Entry state: entry.price = null. The $90.65 after-hours reference is not an executable entry. A simple unlevered common-stock long does not ordinarily require a locate or borrow, but a fresh regular-session quote, bid, ask, spread, depth, venue, volume quality, and exit-liquidity audit remains required.
Conditional path: Reassess after the Sept. 1 Q1 release and call. Require organic portfolio growth, margin after known exclusions, operating cash, Diabetes separation state, current claims, and the denominator before any status upgrade.
Targets: Top $111.00, base $103.00, bottom $86.50, with probabilities of 25%, 50%, and 25%. These are scenario levels, not guaranteed exits.
Invalidation: Remove the thesis if the guide, recurring margin, cash conversion, separation, product, regulatory, claims, denominator, or market-structure tests fail. Unresolved evidence stays blocked.
Horizon: Next 90 calendar days, subject to earlier invalidation or a material catalyst change.
Do not trade: Do not express the idea if the only support is the dividend record, trailing or forward P/E comparison, Cardiac Ablation headline, non-GAAP EPS, or an unfinalized Diabetes structure. Do not use options, leverage, margin, or market orders without a separately verified instrument-level risk and execution contract.

Sources

Medtronic FY26 fourth-quarter results - official June 3, 2026 release; Q4 and FY26 revenue, product growth, margins, cash flow, dividend, FY27 guide, and Diabetes separation structure.
Medtronic FY26 financial schedules - official segment, U.S., international, GAAP, non-GAAP, and cash-flow schedules.
Medtronic Investor Relations overview - official current event page; Sept. 1, 2026 Q1 FY27 release and Q&A timing.
Yahoo Finance MDT quote - finance-feed after-hours context observed at 2026-08-31 23:15:00 UTC; price, change, intraday range, volume, provider market capitalization, and provider P/E/EPS.
Palo Alto Networks fiscal third-quarter 2026 results - candidate comparison; Q3 revenue, NGS ARR, RPO, cash flow, and FY26 guide.
Palo Alto Networks fiscal fourth-quarter 2026 results notice - candidate comparison; Sept. 1, 2026 after-close reporting and webcast schedule.
Yahoo Finance PANW quote - candidate market context observed at 2026-08-31 22:39:20 UTC.
Daktronics Q1 FY27 results notice - candidate comparison; Sept. 2, 2026 pre-market reporting and call schedule.
Daktronics FY26 fourth-quarter results - candidate comparison; record FY26 orders, sales, backlog, margin, and FY27 operating framework.
Yahoo Finance DAKT quote - candidate market context observed at 2026-08-31 21:35:00 UTC.
BlackBerry first-quarter fiscal year 2027 results - candidate comparison; Q1 revenue, QNX and Secure Communications growth, ARR, GAAP profit, and operating cash flow.
BlackBerry investor relations overview - candidate comparison; planned Q2 FY27 earnings date around Sept. 24, 2026 and current financial calendar.
Yahoo Finance BB quote - candidate market context observed at 2026-08-31 23:19:38 UTC.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	5/5	A mature-company label and trailing multiple sit beside broad Q4 organic growth, product share gains, a forward guide, and recurring cash
Evidence base	4/5	The June primary release and schedules are detailed; Q1 FY27 evidence is pending and the guide contains calendar, M&A, and separation effects
Positioning and flows	3/5	Volume and issuer capital-return history are visible, but direct short, options, dealer, fund-flow, and holder evidence is missing
Catalyst path	5/5	Q1 release, call, segment bridge, cash reconciliation, and Diabetes structure are dated or observable
Payoff architecture	4/5	Reference-only base is above 10% with a modeled adverse case below 5%, but event tails and costs remain unresolved
Invalidation discipline	5/5	Guide, margin, cash, separation, product, denominator, and execution cancellation tests are explicit
Differentiated insight	4/5	The disagreement is forward growth and cash quality versus a mature-company label, not a dividend or product slogan
Client value	4/5	The evidence sequence is useful whether Q1 confirms, narrows, or breaks the FY27 framework

Total: 34/40. Classification: Watchlist. The score clears the research threshold, but it cannot override the null entry, after-hours context, pending Q1 results, unresolved separation, missing positioning evidence, or unproven adverse bound.

Bottom Line

MDT is the strongest current U.S. long research candidate because its next catalyst can adjudicate both growth and cash quality in one print. The upside case is concrete: 6.6% Q4 organic growth, 78% global Cardiac Ablation growth, 124% U.S. Cardiac Ablation growth, FY27 organic guidance of 6.75% to 7.25%, and $5.426 billion of FY26 free cash flow. The counterparty is concrete too: Q4 non-GAAP margin fell, the guide includes a 53rd week and M&A, and the Diabetes separation is not final. The correct status is Watchlist with a null entry. The Q1 segment, margin, cash, separation, and denominator bridges decide whether a mature medtech discount is stale or deserved.

AI Illustration Prompt

Create a realistic editorial illustration for The Mispricing Desk about Medtronic (MDT): a quiet medical-device portfolio review room at dawn, with a hospital corridor and restrained cardiac-monitor light visible through glass. In the foreground, place two separate physical ledgers on an off-white clinical desk. The left ledger is the operating bridge and must show exact readable figures $90.65 after-hours reference, Q4 revenue $9.807B, Q4 organic growth 6.6%, Cardiac Ablation global growth 78%, Cardiac Ablation U.S. growth 124%, FY27 organic guide 6.75% to 7.25%, and FY27 non-GAAP EPS $5.90 to $6.00. The right ledger is the cash and separation bridge and must show FY26 free cash flow $5.426B, cash and investments $9.2B, FY26 shareholder returns $4.2B, quarterly dividend $0.72, Q4 non-GAAP margin 25.5%, MiniMed payment 160 bps, tariffs 80 bps, Diabetes structure not final, Q1 release Sept. 1 at 5:45 a.m. CT, and a red stamped label ENTRY UNVERIFIED. Add a restrained checklist for organic portfolio growth, margin after exclusions, operating cash, separation costs, and the ordinary-share denominator. Use charcoal, surgical white, muted teal, cool cobalt, brushed steel, soft hospital green, and one restrained rust-red risk accent with documentary financial-journalism lighting. No generic candlestick chart, rockets, coins, hype, invented logos, or extra numbers. Integrate a subtle readable “The Mispricing Desk” watermark into the ledger divider. Wide 16:9 composition, premium magazine art direction, crisp typography, no personalized advice.